Pfizer Q3 Adjusted EPS $(0.17) Beats $(0.32) Estimate, Sales $13.23B Beat $12.72B Estimate
Portfolio Pulse from Benzinga Newsdesk
Pfizer reported Q3 losses of $(0.17) per share, beating the analyst consensus estimate of $(0.32) by 46.88%. This is a 109.55% decrease from last year's earnings. The company also reported quarterly sales of $13.23 billion, beating the estimate of $12.72 billion by 4.03%. This is a 41.55% decrease from last year's sales.
October 31, 2023 | 10:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's Q3 results beat estimates on both earnings and sales, despite significant YoY decreases. This could potentially signal resilience in the face of challenging conditions.
Pfizer's better-than-expected Q3 results, despite significant YoY decreases, could be seen as a positive sign by investors. This could potentially lead to increased investor confidence and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100